Comparison between AMS700TM CX and ColoplastTM Titan inflatable penile prostheses for Peyronie’s disease treatment and remodelling: Clinical outcomes and patient satisfaction.
Eric Chung1,2 , Matthew Solomon1,2, Ling De Young2 and Gerald B Brock2
1 Department of Urology, Princess Alexandra Hospital, Brisbane, QLD Australia
2 Division of Urology, St Joseph Health Care, London, ON Canada
- Inflatable penile prosthesis (IPP) is indicated in men with Peyronie’s disease (PD) and medically-refractory erectile dysfunction (ED).
- The implantation of penile prosthesis with simultaneous manual penile remodelling allows for men with PD and ED to undergo a single procedure aimed at correcting both the penile deformity/curvature and ED.
- To date, there is no published literature comparing AMS700TM CX and ColoplastTM Titan IPP in patient group.
- A total of 138 patients with an average age of 57.7 (32 to 80) underwent either AMS 700TM CX (88 patients) or ColoplastTM Titans (50 patients) IPP implantation during the 5-year period.
- The majority of patients (91%) required only one IPP implantation.
- The IPP clinical outcomes include 8 (6%) revision surgery for device malfunction and 3 (2%) device explantation for prosthesis infection.
- While there was no statistically significance in device survival and infection between the 2 devices, the trend favoured AMS700 CX over Titan (5-year Kaplan-Meier estimates of mechanical survival were 91% vs. 87%, p<0.05) (Figure 1) and both IPPs provided similar penile straightening without the need for revision surgery.
- Most men (79%) reported great satisfaction following IPP implantation with greater than two thirds of men reported greater self-confidence and 82% of patients would undergo the same operation again (Table 1).
To evaluate the clinical outcomes and patient satisfaction following AMS700TM CX and Titan IPPs implantation.
- A retrospective review of clinical database and prospective independent telephone survey were undertaken in all men who underwent IPP implantation for PD between January 2006 and December 2010.
- Patient demographics, International Index of Erectile Function (IIEF-5) scores, preoperative PD characteristics, previous PD therapies and types of IPP implanted were reviewed.
- Follow-up assessments included surgical outcomes and overall patient satisfactions such as ease and frequency of use, patient and partner satisfaction, and self esteem.
Figure 1: Kaplan-Meier estimates of survival from mechanical failure showed trend toward enhanced AMS 700 CX over Titan IPP that did not reach statistical significance at 5 years (p>0.05).
Table 1: Selected characteristics of survey responders
- IPP implantation and remodelling appears to provide permanent penile straightening without an increase risk in revision surgery.
- AMS 700TM CX and Titan IPPs were similar in device survival and patient satisfaction.
Poster presentation sponsor